Tempus AI (NASDAQ:TEM) Stock Price Breaks Below 200-Day Moving Average on Insider Selling

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) shares crossed below its 200-day moving average during trading on Friday following insider selling activity. The stock has a 200-day moving average of $57.55 and traded as low as $53.26. Tempus AI shares last traded at $53.9760, with a volume of 7,412,144 shares trading hands.

Specifically, CAO Ryan Bartolucci sold 1,540 shares of Tempus AI stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total value of $97,050.80. Following the sale, the chief accounting officer directly owned 59,264 shares in the company, valued at $3,734,817.28. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 10,247 shares of the stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total value of $645,765.94. Following the transaction, the chief executive officer directly owned 652,216 shares of the company’s stock, valued at $41,102,652.32. This trade represents a 1.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In other news, CFO James Rogers sold 7,079 shares of Tempus AI stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total value of $446,118.58. Following the completion of the transaction, the chief financial officer owned 98,945 shares of the company’s stock, valued at $6,235,513.90. This trade represents a 6.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analyst Ratings Changes

A number of research analysts recently commented on TEM shares. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target on shares of Tempus AI in a research note on Thursday. Roth Capital assumed coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective for the company. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Stifel Nicolaus reduced their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Finally, BTIG Research upped their target price on Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.37.

View Our Latest Analysis on TEM

Latest Tempus AI News

Here’s some of the latest news about TEM:

  • Positive Sentiment: The company extended its strategic collaboration with AstraZeneca. Separate investor coverage cited data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027, supporting the longer-term growth case. AstraZeneca collaboration Investor takeaways
  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating
  • Neutral Sentiment: Several senior executives, including the CEO and CFO, sold shares. The filings say the sales covered tax withholding obligations on vested equity awards, making them less indicative of a change in confidence, though multiple insider sales may still draw investor attention. Insider sale report

Tempus AI Stock Performance

The company has a current ratio of 2.61, a quick ratio of 2.48 and a debt-to-equity ratio of 2.70. The company has a market cap of $9.85 billion, a P/E ratio of -50.92 and a beta of 3.61. The company has a 50 day moving average price of $72.79 and a 200-day moving average price of $57.55.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. During the same period last year, the firm posted ($0.46) earnings per share. Tempus AI’s revenue was up 23.1% compared to the same quarter last year. On average, equities analysts expect that Tempus AI, Inc. will post -1.20 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in TEM. V Square Quantitative Management LLC bought a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $27,000. EMC Capital Management acquired a new stake in Tempus AI in the second quarter valued at approximately $29,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Tempus AI in the third quarter valued at approximately $33,000. Ulland Investment Advisors LLC bought a new stake in shares of Tempus AI during the third quarter worth $41,000. Finally, Heritage Family Offices LLP bought a new stake in shares of Tempus AI during the third quarter worth $45,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

See Also

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.